| Evidence domain | Source type | Key finding with exact quantitative detail | Interpretation / limitation | Citation context ID or DOI/PMID |
|---|---|---|---|---|
| Human genetics: original DFNA50 families | Human familial linkage/variant study | Two Spanish families with autosomal dominant progressive nonsyndromic hearing loss carried MIR96 seed-region variants **+13G>A** and **+14C>A**; both affect conserved seed nucleotides and were not found in **462 hearing controls**. The **+13G>A** family had affected frequencies across the audiogram, whereas **+14C>A** caused more severe **high-frequency** loss. Mutant miRNA levels were reported as about **20% of wild type**. | Foundational evidence for DFNA50 due to MIR96 seed mutations; quantitative clinical details in available excerpts are limited, and PMIDs were not provided in the retrieved context. | (pqac-00000002, pqac-00000007) |
| Human genetics: Italian family, precursor variant discovery | Human case-control + family segregation + in vitro functional assay | Screening of **882 NSHL patients** and **836/839 normal-hearing Italian controls** identified **MIR96 c.57T>C** (reported as miR-96(+57T>C); NR_029512.1:c.57T>C; NT_007933.15:g.67447397A>G) in one autosomal dominant family. Reported onset was about **25–40 years** with slow progression; the proband progressed from mild hearing loss at ~25 years to severe at **45** and profound in the **sixth decade**. Variant was present in **3 normal-hearing children**, supporting age-dependent/incomplete penetrance. | First non-seed MIR96 DFNA50 allele; phenotype appears milder/later than seed mutations. Control denominator appears as 836 in abstract text and 839 in results text of available excerpts. | (pqac-00000004, pqac-00000005, pqac-00000020, pqac-00000021) |
| In vitro mechanism: precursor-processing defect | In vitro transient-expression / qRT-PCR | For the Italian **+57T>C** precursor variant, mature **miR-96** was reduced by **85%** (**P=0.0006**) and **miR-96\*** by **77%** (**P=0.019**), while precursor levels were unaffected; compensatory mutation restored expression. | Supports a **quantitative** pathogenic mechanism through altered hairpin structure and impaired Dicer processing, rather than altered seed specificity. | (pqac-00000021) |
| Mouse model: Dmdo discovery and phenotype | Animal model (ENU mutant mouse) | The **diminuendo (Dmdo)** mouse carries an **A>T** substitution in the Mir96 seed region. Heterozygotes lost the Preyer reflex between **4–6 weeks**, and compound action potential/ABR-type thresholds were raised by about **60 dB** at **4 weeks**; homozygotes had **no cochlear responses**. Microarray showed **96 transcripts** significantly altered, with downregulation of **Slc26a5, oncomodulin/Ocm, Gfi1, Ptprq, Pitpnm1**. | Strong mechanistic model for progressive DFNA50-like hearing loss; background is mouse, not human, and transcriptomics were whole-organ rather than cell-specific. | (pqac-00000014) DOI:10.1038/ng.369 |
| Hair-cell-specific transcriptomics | Animal model (newborn Mir96Dmdo hair-cell RNA-seq) | First HC-specific RNA-seq dataset from newborn Mir96Dmdo mice identified **215 upregulated** and **428 downregulated** genes in homozygous mutant hair cells versus wild type; highlighted downregulated deafness/development genes included **Myo15a, Myo7a, Ush1c, Gfi1, Ptprq**. | Refines cell-autonomous consequences in hair cells; newborn time point may not capture later degenerative stages. | (pqac-00000022) DOI:10.3389/fauot.2024.1400576 |
| Human-mutation knock-in transcriptomics | Animal model (2024 humanized Mir96 knock-in mice) | In 2024 knock-in mice carrying human MIR96 variants, homozygous **Mir96+13G>A** had **328 DEGs** and homozygous **Mir96+14C>A** had **693 DEGs** by RNA-seq. Table summary reports heterozygous **Mir96+14C>A** with progressive hearing loss, while **Mir96+13G>A** heterozygotes had normal hearing in mice. | Demonstrates mutation-specific biology and supports gain-of-novel-target effects; mismatch between human and mouse heterozygous +13G>A phenotype is a limitation. | (pqac-00000015, pqac-00000017) DOI:10.1186/s13073-024-01394-5 |
| Pharmacologic proof-of-concept | Animal model therapeutic experiment | Transcriptome-based drug repurposing selected **amitriptyline**. Mir96+14C>A mice received **200 µg/mL** or **400 µg/mL** in drinking water; hearing loss in heterozygotes was **significantly delayed at 24–36 kHz**, most visibly at **30 kHz at 4 weeks**, but **400 µg/mL** did not improve over **200 µg/mL** and homozygotes did not improve. | Proof of concept for pharmacologic delay of progression; effect was **temporary** and mouse doses were higher than standard human dosing, limiting translational use. | (pqac-00000015, pqac-00000016) DOI:10.1186/s13073-024-01394-5 |
| Adult genome editing | Animal model gene-editing therapy | 2024 study developed **AAV-delivered SaCas9-KKH** with sgRNA against **Mir96 14C>A** and treated presymptomatic **3-week-old** and symptomatic **6-week-old** adult heterozygous mice. Hearing improved **long term**, with better efficacy at the younger age; authors also reported transient Cas9 expression and **no evidence of AAV genomic integration**. A dual-AAV “master” system targeted **all known human MIR96 mutations**. | Highly relevant preclinical therapy for dominant MIR96 disease; available excerpts did not provide exact editing percentages or ABR/DPOAE delta values. | (pqac-00000001, pqac-00000009, pqac-00000012) DOI:10.1126/scitranslmed.adn0689 |


*Table: This table summarizes the strongest human, in vitro, and animal evidence for DFNA50 caused by MIR96 variants, including core family reports, mechanistic assays, transcriptomics, and 2024 therapeutic studies. It is useful as a compact citation-ready map of what is known and where current evidence remains limited.*